Cell cycle checkpoints and beyond: Exploiting the ATR/CHK1/WEE1 pathway for the treatment of PARP inhibitor–resistant cancer is a research paper published in Pharmacological Research (2022). On theSindex it has a DataRank of 2.9. It has been cited 111 times, with 104 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.708
From this paper's citation signal
Citation Network Contribution
2.2
From 82 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 104 citers.
National Cancer Institute
Grant: BC011525
Doris Duke Charitable Foundation
Grant: 2014194
Intramural NIH HHS
Grant: Z99 CA999999
Intramural NIH HHS
Grant: ZIA BC011525
National Institutes of Health
Grant: 1ZIABC011525-06
Leveraging DNA damage repair pathways as therapeutic targets in womens cancers
National Institutes of Health
American Association for Dental, Oral, and Craniofacial Research
National Cancer Institute
FWCI
9.12
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals